Cuiqing Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cuiqing Huang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Amartya Sau
Department of Physics Jadavpur University Kolkata India
1 shared publication- Bing Guo
Shenzhen Key Laboratory of Advanced Functional Carbon Materials Research and Comprehensive Application, School of Science, Harbin Institute of Technology, Shenzhen, China
1 shared publication - Duo Wang
The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China
1 shared publication Guanhua Qiu
Department of Ultrasound and Department of Radiology, Affiliated Tumor Hospital of Guangxi Medical University
1 shared publicationJhilik Roy
Department of Physics Jadavpur University Kolkata India
1 shared publication- Jifeng Chen
The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People’s Republic of China
1 shared publication
Latest Publications
NIR‐II Fluorescent Nanoplatforms with Defect‐Regulated Piezoelectricity for Dual NIR‐II/MRI‐Guided, Hypoxia‐Resilient Piezo‐Chemodynamic Therapy and cGAS‐STING Activation in Orthotopic Liver Tumor
The development of multifunctional theranostic nanoplatforms with second near‐infrared (NIR‐II) fluorescence and magnetic resonance imaging (MRI), which enable deep‐tissue imaging, hypoxia‐tolerant ROS generation via on‐demand, rapid piezodynamic therapy (PZDT) and sustained tumor‐microenvironment‐activated chemodynamic therapy (CDT), together with robust immunomodulation, remains a critical challenge in tumor therapy. Here, one‐pot solvothermal synthesis of Mn, Yb, and Er co‐doped BaTiO 3 (FMBTO) is reported, a first‐in‐class NIR‐II fluorescence‐emitting piezoelectric nanocomposite that integrates imaging, catalytic therapy, and innate immune activation within a single framework. Yb 3+ /Er 3+ doping imparts intrinsic NIR‐II fluorescence, eliminating the need for external fluorophores or downconversion nanoparticles, while Mn 2+ incorporation enables piezoelectric enhancement, T1‐weighted MRI contrast, Fenton‐like chemodynamic catalysis, and potent cGAS‐STING immune activation. Defect engineering within the BTO lattice significantly enhances piezocatalytic reactive oxygen species (ROS) generation, even under severe hypoxia, and simultaneously promotes Mn 2+ ‐mediated H 2 O 2 decomposition to liberate molecular oxygen (O 2 ), thereby reversing hypoxia and downregulating HIF‐1α. In an orthotopic liver tumor model, FMBTO demonstrates strong tumor accumulation, NIR‐II/MRI‐guided treatment precision, and ultrasound (US)‐triggered PZDT‐CDT synergy, leading to extensive tumor apoptosis, immune‐cell recruitment, and robust STING pathway activation. Collectively, FMBTO establishes a versatile nanotheranostic paradigm that couples deep‐tissue imaging with oxygen‐independent ROS production and innate immune stimulation, offering a powerful strategy for treating hypoxic and immunosuppressed solid tumors.
NIR‐II Fluorescent Nanoplatforms with Defect‐Regulated Piezoelectricity for Dual NIR‐II/MRI‐Guided, Hypoxia‐Resilient Piezo‐Chemodynamic Therapy and cGAS‐STING Activation in Orthotopic Liver Tumor
The development of multifunctional theranostic nanoplatforms with second near‐infrared (NIR‐II) fluorescence and magnetic resonance imaging (MRI), which enable deep‐tissue imaging, hypoxia‐tolerant ROS generation via on‐demand, rapid piezodynamic therapy (PZDT) and sustained tumor‐microenvironment‐activated chemodynamic therapy (CDT), together with robust immunomodulation, remains a critical challenge in tumor therapy. Here, one‐pot solvothermal synthesis of Mn, Yb, and Er co‐doped BaTiO 3 (FMBTO) is reported, a first‐in‐class NIR‐II fluorescence‐emitting piezoelectric nanocomposite that integrates imaging, catalytic therapy, and innate immune activation within a single framework. Yb 3+ /Er 3+ doping imparts intrinsic NIR‐II fluorescence, eliminating the need for external fluorophores or downconversion nanoparticles, while Mn 2+ incorporation enables piezoelectric enhancement, T1‐weighted MRI contrast, Fenton‐like chemodynamic catalysis, and potent cGAS‐STING immune activation. Defect engineering within the BTO lattice significantly enhances piezocatalytic reactive oxygen species (ROS) generation, even under severe hypoxia, and simultaneously promotes Mn 2+ ‐mediated H 2 O 2 decomposition to liberate molecular oxygen (O 2 ), thereby reversing hypoxia and downregulating HIF‐1α. In an orthotopic liver tumor model, FMBTO demonstrates strong tumor accumulation, NIR‐II/MRI‐guided treatment precision, and ultrasound (US)‐triggered PZDT‐CDT synergy, leading to extensive tumor apoptosis, immune‐cell recruitment, and robust STING pathway activation. Collectively, FMBTO establishes a versatile nanotheranostic paradigm that couples deep‐tissue imaging with oxygen‐independent ROS production and innate immune stimulation, offering a powerful strategy for treating hypoxic and immunosuppressed solid tumors.
- Open Access
- 11 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1207
Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer
Abnormal tumor vasculature and a hypoxic tumor microenvironment (TME) limit the effectiveness of conventional cancer treatment. Recent studies have shown that antivascular strategies that focus on antagonizing the hypoxic TME and promoting vessel normalization effectively synergize to increase the antitumor efficacy of conventional therapeutic regimens. By integrating multiple therapeutic agents, well-designed nanomaterials exhibit great advantages in achieving higher drug delivery efficiency and can be used as multimodal therapy with reduced systemic toxicity. In this review, strategies for the nanomaterial-based administration of antivascular therapy combined with other common tumor treatments, including immunotherapy, chemotherapy, phototherapy, radiotherapy, and interventional therapy, are summarized. In particular, the administration of intravascular therapy and other therapies with the use of versatile nanodrugs is also described. This review provides a reference for the development of multifunctional nanotheranostic platforms for effective antivascular therapy in combined anticancer treatments.
- 11 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1207
Open AccessNanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer
Abnormal tumor vasculature and a hypoxic tumor microenvironment (TME) limit the effectiveness of conventional cancer treatment. Recent studies have shown that antivascular strategies that focus on antagonizing the hypoxic TME and promoting vessel normalization effectively synergize to increase the antitumor efficacy of conventional therapeutic regimens. By integrating multiple therapeutic agents, well-designed nanomaterials exhibit great advantages in achieving higher drug delivery efficiency and can be used as multimodal therapy with reduced systemic toxicity. In this review, strategies for the nanomaterial-based administration of antivascular therapy combined with other common tumor treatments, including immunotherapy, chemotherapy, phototherapy, radiotherapy, and interventional therapy, are summarized. In particular, the administration of intravascular therapy and other therapies with the use of versatile nanodrugs is also described. This review provides a reference for the development of multifunctional nanotheranostic platforms for effective antivascular therapy in combined anticancer treatments.
- Open Access
- 14 February 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 756489
Cetuximab Combined With Sonodynamic Therapy Achieves Dual-Modal Image Monitoring for the Treatment of EGFR-Sensitive Non-Small-Cell Lung Cancer
Background: Blocking signaling by epidermal growth factor receptor (EGFR), can effectively inhibit the proliferation and differentiation of non-small-cell lung cancer (NSCLC). Additionally, an increasing number of NSCLC patients have treatment limitations caused by EGFR overexpression or mutations. Therefore, we constructed a nanotherapy platform consisting of cetuximab (CTX) to target EGFR-sensitive NSCLC with an iron tetroxide core loading the sound-sensitive agent IR780 for dual-mode imaging diagnosis by combining targeting and sonodynamic therapy (SDT) to reshape the tumor microenvironment (TME), enhance the SDT antitumor effects and improve the therapeutic effects of EGFR sensitivity.Methods: IR780@INPs were prepared by reverse rotary evaporation, CTX was adsorbed/coupled to obtain IR780@INPs-CTX, and the morphology and structure were characterized. Intracellular ROS levels and cell apoptosis first verified its killing effects against tumor cells. Then, a nude mouse lung cancer subcutaneous xenograft model was established with HCC827 cells. A real-time fluorescence IVIS imaging system determined the targeting and live distribution of IR780@INPs-CTX in the transplanted tumors and the imaging effects of the T2 sequence of the INPs by magnetic resonance imaging (MRI) 0 h, 2 h, 4 h and 6 h after administration to confirm drug efficacy.Results: In vitro, US+IR780@INPs-CTX produced a large amount of ROS after SDT to induce cell apoptosis, and significant cell death after live/dead staining was observed. In vivo fluorescence imaging showed the IR780@INPs-CTX was mainly concentrated in the tumor with a small amount in the liver. MRI displayed rapid enrichment of the IR780@INPs into tumor tissue 0h after injection and the T2 signal intensity gradually decreases with time without obvious drug enrichment in the surrounding tissues. In vivo, at the end of treatment, the US+IR780@INPs-CTX group showed disappearance or a continued decrease in tumor volume, indicating strong SDT killing effects.Conclusion: The combination of CTX and SDT is expected to become a novel treatment for EGFR-sensitive NSCLC.
- 14 February 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 756489
Open AccessCetuximab Combined With Sonodynamic Therapy Achieves Dual-Modal Image Monitoring for the Treatment of EGFR-Sensitive Non-Small-Cell Lung Cancer
Background: Blocking signaling by epidermal growth factor receptor (EGFR), can effectively inhibit the proliferation and differentiation of non-small-cell lung cancer (NSCLC). Additionally, an increasing number of NSCLC patients have treatment limitations caused by EGFR overexpression or mutations. Therefore, we constructed a nanotherapy platform consisting of cetuximab (CTX) to target EGFR-sensitive NSCLC with an iron tetroxide core loading the sound-sensitive agent IR780 for dual-mode imaging diagnosis by combining targeting and sonodynamic therapy (SDT) to reshape the tumor microenvironment (TME), enhance the SDT antitumor effects and improve the therapeutic effects of EGFR sensitivity.Methods: IR780@INPs were prepared by reverse rotary evaporation, CTX was adsorbed/coupled to obtain IR780@INPs-CTX, and the morphology and structure were characterized. Intracellular ROS levels and cell apoptosis first verified its killing effects against tumor cells. Then, a nude mouse lung cancer subcutaneous xenograft model was established with HCC827 cells. A real-time fluorescence IVIS imaging system determined the targeting and live distribution of IR780@INPs-CTX in the transplanted tumors and the imaging effects of the T2 sequence of the INPs by magnetic resonance imaging (MRI) 0 h, 2 h, 4 h and 6 h after administration to confirm drug efficacy.Results: In vitro, US+IR780@INPs-CTX produced a large amount of ROS after SDT to induce cell apoptosis, and significant cell death after live/dead staining was observed. In vivo fluorescence imaging showed the IR780@INPs-CTX was mainly concentrated in the tumor with a small amount in the liver. MRI displayed rapid enrichment of the IR780@INPs into tumor tissue 0h after injection and the T2 signal intensity gradually decreases with time without obvious drug enrichment in the surrounding tissues. In vivo, at the end of treatment, the US+IR780@INPs-CTX group showed disappearance or a continued decrease in tumor volume, indicating strong SDT killing effects.Conclusion: The combination of CTX and SDT is expected to become a novel treatment for EGFR-sensitive NSCLC.